Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract

Nature Medicine

Volumn 18, Issue 10, 2012, Pages 1531-1538

  Minamiyama, Makoto ^a   Katsuno, Masahisa ^a   Adachi, Hiroaki ^a   Doi, Hideki ^a   Kondo, Naohide ^a   Iida, Madoka ^a   Ishigaki, Shinsuke ^a   Fujioka, Yusuke ^a   Matsumoto, Shinjiro ^a   Miyazaki, Yu ^a   Tanaka, Fumiaki ^a   Kurihara, Hiroki ^b   Sobue, Gen ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CALCITONIN GENE RELATED PEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; NARATRIPTAN; POLYGLUTAMINE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC CODE; KENNEDY DISEASE; MALE; MOTONEURON; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CALCITONIN; CELL SURVIVAL; CELLS, CULTURED; DUAL SPECIFICITY PHOSPHATASE 1; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MICE; MICE, TRANSGENIC; MOTOR NEURON DISEASE; MUSCULAR DISORDERS, ATROPHIC; PEPTIDES; PIPERIDINES; PROTEIN PRECURSORS; RECEPTORS, ANDROGEN; RNA INTERFERENCE; RNA, SMALL INTERFERING; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SPINAL CORD; TRINUCLEOTIDE REPEAT EXPANSION; TRYPTAMINES;

EID: 84870282997     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2932     Document Type: Article

References (52)

1. Ross, C.A. & Tabrizi, S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83-98 (2011).
2. Gatchel, J.R. & Zoghbi, H.Y. Diseases of unstable repeat expansion: mechanisms and common principles. Nat. Rev. Genet. 6, 743-755 (2005).
3. Finsterer, J. Perspectives of Kennedy's disease. J. Neurol. Sci. 298, 1-10 (2010).
4. Katsuno, M. et al. Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA). Exp. Neurol. 200, 8-18 (2006).
5. La Spada, A.R., Wilson, E.M., Lubahn, D.B., Harding, A.E. & Fischbeck, K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 77-79 (1991).
6. Schmidt, B.J., Greenberg, C.R., Allingham-Hawkins, D.J. & Spriggs, E.L. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 59, 770-772 (2002).
7. Sobue, G. et al. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 112, 209-232 (1989).
8. Adachi, H. et al. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain 128, 659-670 (2005).
9. Bauer, P.O. & Nukina, N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J. Neurochem. 110, 1737-1765 (2009).
10. Shao, J. & Diamond, M.I. Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum. Mol. Genet. 16 Spec No. 2, R115-R123 (2007).
11. Katsuno, M. et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35, 843-854 (2002).
12. Takeyama, K. et al. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 35, 855-864 (2002).
13. Nedelsky, N.B. et al. Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron 67, 936-952 (2010).
14. Minamiyama, M. et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 13, 1183-1192 (2004).
15. Katsuno, M. et al. Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration. J. Neurosci. 26, 12106-12117 (2006).
16. Ranganathan, S. et al. Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Hum. Mol. Genet. 18, 27-42 (2009).
17. Katsuno, M. et al. Disrupted transforming growth factor-β signaling in spinal and bulbar muscular atrophy. J. Neurosci. 30, 5702-5712 (2010).
18. Steffan, J.S. et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413, 739-743 (2001).
19. Butler, R. & Bates, G.P. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat. Rev. Neurosci. 7, 784-796 (2006).
20. Luthi-Carter, R. et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9, 1259-1271 (2000).
21. Obrietan, K. & Hoyt, K.R. CRE-mediated transcription is increased in Huntington's disease transgenic mice. J. Neurosci. 24, 791-796 (2004).
22. Sugars, K.L. & Rubinsztein, D.C. Transcriptional abnormalities in Huntington disease. Trends Genet. 19, 233-238 (2003).
23. Mo, K. et al. Microarray analysis of gene expression by skeletal muscle of three mouse models of Kennedy disease/spinal bulbar muscular atrophy. PLoS ONE 5, e12922 (2010).
24. Ho, T.W., Edvinsson, L. & Goadsby, P.J. CGRP and its receptors provide new insights into migraine pathophysiology. Nat. Rev. Neurol. 6, 573-582 (2010).
25. Katsuno, M. et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat. Med. 9, 768-773 (2003).
26. Popper, P. & Micevych, P.E. The effect of castration on calcitonin gene-related peptide in spinal motor neurons. Neuroendocrinology 50, 338-343 (1989).
27. Ma, W. et al. Localization and modulation of calcitonin gene-related peptide-receptor component protein-immunoreactive cells in the rat central and peripheral nervous systems. Neuroscience 120, 677-694 (2003).
28. Walker, C.S., Conner, A.C., Poyner, D.R. & Hay, D.L. Regulation of signal transduction by calcitonin gene-related peptide receptors. Trends Pharmacol. Sci. 31, 476-483 (2010).
29. Durham, P.L. & Russo, A.F. New insights into the molecular actions of serotonergic antimigraine drugs. Pharmacol. Ther. 94, 77-92 (2002).
30. Jhee, S.S., Shiovitz, T., Crawford, A.W. & Cutler, N.R. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin. Pharmacokinet. 40, 189-205 (2001).
31. Durham, P.L. & Russo, A.F. Serotonergic repression of mitogen-activated protein kinase control of the calcitonin gene-related peptide enhancer. Mol. Endocrinol. 12, 1002-1009 (1998).
32. Morfni, G. et al. JNK mediates pathogenic effects of polyglutamine- expanded androgen receptor on fast axonal transport. Nat. Neurosci. 9, 907-916 (2006).
33. Serra, H.G. et al. Gene profling links SCA1 pathophysiology to glutamate signaling in Purkinje cells of transgenic mice. Hum. Mol. Genet. 13, 2535-2543 (2004).
34. Becanovic, K. et al. Transcriptional changes in Huntington disease identifed using genome-wide expression profling and cross-platform analysis. Hum. Mol. Genet. 19, 1438-1452 (2010).
35. Zheng, L.F. et al. Calcitonin gene-related peptide dynamics in rat dorsal root ganglia and spinal cord following different sciatic nerve injuries. Brain Res. 1187, 20-32 (2008).
36. Ringer, C., Weihe, E. & Schutz, B. Calcitonin gene-related peptide expression levels predict motor neuron vulnerability in the superoxide dismutase 1-G93A mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 45, 547-554 (2012).
37. Ringer, C., Weihe, E. & Schutz, B. Pre-symptomatic alterations in subcellular betaCGRP distribution in motor neurons precede astrogliosis in ALS mice. Neurobiol. Dis. 35, 286-295 (2009).
38. Di Angelantonio, S., Giniatullin, R., Costa, V., Sokolova, E. & Nistri, A. Modulation of neuronal nicotinic receptor function by the neuropeptides CGRP and substance P on autonomic nerve cells. Br. J. Pharmacol. 139, 1061-1073 (2003).
39. Benemei, S., Nicoletti, P., Capone, J.A. & Geppetti, P. Pain pharmacology in migraine: focus on CGRP and CGRP receptors. Neurol. Sci. 28 (suppl. 2), S89-S93 (2007).
40. Disa, J., Parameswaran, N., Nambi, P. & Aiyar, N. Involvement of cAMP-dependent protein kinase and pertussis toxin-sensitive G-proteins in CGRP mediated JNK activation in human neuroblastoma cell line. Neuropeptides 34, 229-233 (2000).
41. Borsello, T. & Forloni, G. JNK signalling: a possible target to prevent neurodegeneration. Curr. Pharm. Des. 13, 1875-1886 (2007).
42. Perrin, V. et al. Implication of the JNK pathway in a rat model of Huntington's disease. Exp. Neurol. 215, 191-200 (2009).
43. Mehan, S., Meena, H., Sharma, D. & Sankhla, R. JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities. J. Mol. Neurosci. 43, 376-390 (2011).
44. Young, J.E. et al. Polyglutamine-expanded androgen receptor truncation fragments activate a Bax-dependent apoptotic cascade mediated by DP5/Hrk. J. Neurosci. 29, 1987-1997 (2009).
45. Edvinsson, L. & Goadsby, P.J. Neuropeptides in migraine and cluster headache. Cephalalgia 14, 320-327 (1994).
46. Katsuno, M. et al. for the Japan SBMA Interventional Trial for TAP-144-SR (JASMITT) study group. Effcacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9, 875-884 (2010).
47. Fernández-Rhodes, L.E. et al. Effcacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol. 10, 140-147 (2011).
48. Niwa, H., Yamamura, K. & Miyazaki, J. Effcient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108, 193-199 (1991).
49. Waza, M. et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med. 11, 1088-1095 (2005).
50. Oh-hashi, Y. et al. Elevated sympathetic nervous activity in mice defcient in alphaCGRP. Circ. Res. 89, 983-990 (2001).
51. Adachi, H. et al. CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. J. Neurosci. 27, 5115-5126 (2007).
52. Tokui, K. et al. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum. Mol. Genet. 18, 898-910 (2009).